Lacosamid Zentiva

Lacosamide, the active ingredient in Lacosamid Zentiva, is a sodium channel blocker presented as an oral tablet for oral use. It is indicated for the treatment of partial‑onset seizures in patients with epilepsy. GNH USA supplies Lacosamid Zentiva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lacosamide is an antiepileptic drug that acts on voltage‑gated sodium channels to control seizure activity. - Partial‑onset seizures: reduces seizure frequency as an adjunct therapy in epilepsy patients. - Focal seizures: improves seizure control when added to existing antiepileptic regimens. - Refractory epilepsy: offers an alternative mechanism for patients not responding adequately to other medications.

Lacosamide may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Dizziness: transient sensation of light‑headedness. - Fatigue: increased tiredness or lack of energy. - Nausea: mild to moderate stomach upset. - Diplopia: occasional double vision. - Headache: mild to moderate pain in the head. - Somnolence: tendency to feel sleepy.

Serious or Rare Side Effects: - Suicidal ideation: emergence of thoughts of self‑harm. - Cardiac conduction abnormalities: PR‑interval prolongation or arrhythmia. - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Hypersensitivity: rash, angioedema, or anaphylaxis. - Liver enzyme elevation: significant increase in hepatic transaminases. - Blood dyscrasias: rare cases of agranulocytosis or thrombocytopenia.

When prescribing Lacosamid Zentiva, clinicians should consider several safety measures. - Renal impairment: assess kidney function and adjust dose if necessary. - Hepatic impairment: monitor liver enzymes and consider dose modification. - Cardiac conduction: obtain baseline ECG and watch for PR‑interval changes. - Pregnancy: risk category unknown; avoid unless benefits outweigh potential risks. - Concomitant antiepileptics: monitor for additive CNS depression. - Store at ambient temperature: keep in the original container, protect from moisture.

Lacosamide can interact with other medicines, requiring careful management.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., carbamazepine, phenytoin): may markedly reduce lacosamide plasma levels. - Drugs that prolong PR interval (e.g., quinidine, amiodarone): increase risk of cardiac conduction disturbances.

Moderate Interactions (Monitor Closely): - Other antiepileptic drugs: may enhance central nervous system side‑effects. - Oral contraceptives: lacosamide may reduce contraceptive efficacy; consider additional protection. - Alcohol: combined use can intensify sedation and dizziness.